Clinical Potential of Antigen-specific Therapies in Type 1 Diabetes

Overview

Journal Rev Diabet Stud

Specialty Endocrinology

Date 2013 Jun 28

PMID 23804270

Citations 1

Authors

Ken T Coppieters

Birgit Sehested Hansen

Matthias G von Herrath

Affiliations

Soon will be listed here.

Abstract

In type 1 diabetes (T1D), pancreatic beta-cells are attacked and destroyed by the immune system, which leads to a loss of endogenous insulin secretion. The desirable outcome of therapeutic intervention in autoimmune diseases is the restoration of immune tolerance to prevent organ damage. Past trials with immune suppressive drugs highlight the fact that T1D is in principle a curable condition. However, the barrier in T1D therapy in terms of drug safety is set particularly high because of the predominantly young population and the good prognosis associated with modern exogenous insulin therapy. Thus, there is a general consensus that chronic immune suppression is associated with unacceptable long-term safety risks. On the other hand, immune-modulatory biologicals have recently failed to confer significant protection in phase 3 clinical trials. However, the concept of antigen-specific tolerization may offer a unique strategy to safely induce long-term protection against T1D. In this review, we analyze the potential reasons for the failure of the different tolerization therapies, and describe how the concept of antigen-specific toleraization may overcome the obstacles associated with clinical therapy in T1D.

Citing Articles

Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies.

Coppieters K, von Herrath M Mol Metab. 2014; 3(3):275-83.

PMID: 24749057 PMC: 3986497. DOI: 10.1016/j.molmet.2013.12.005.

References

Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R . Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev. 2006; 23(4):292-8. DOI: 10.1002/dmrr.712. View

Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P . Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986; 2(8499):119-24. DOI: 10.1016/s0140-6736(86)91943-4. View

Hjorth M, Axelsson S, Ryden A, Faresjo M, Ludvigsson J, Casas R . GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol. 2010; 138(1):117-26. DOI: 10.1016/j.clim.2010.10.004. View

Axelsson S, Hjorth M, Ludvigsson J, Casas R . Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum. Diabet Med. 2012; 29(10):1272-8. DOI: 10.1111/j.1464-5491.2012.03710.x. View

. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002; 346(22):1685-91. DOI: 10.1056/NEJMoa012350. View

Lenschow D, Ho S, Sattar H, Rhee L, Gray G, Nabavi N . Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995; 181(3):1145-55. PMC: 2191918. DOI: 10.1084/jem.181.3.1145. View

De Aizpurua H, Wilson Y, Harrison L . Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes. Proc Natl Acad Sci U S A. 1992; 89(20):9841-5. PMC: 50229. DOI: 10.1073/pnas.89.20.9841. View

Buzzetti R, Cernea S, Petrone A, Capizzi M, Spoletini M, Zampetti S . C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes. 2011; 60(11):3067-72. PMC: 3198071. DOI: 10.2337/db10-0560. View

Weiner H, Mackin G, Matsui M, Orav E, Khoury S, Dawson D . Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993; 259(5099):1321-4. DOI: 10.1126/science.7680493. View

10.

Axelsson S, Cheramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E . Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One. 2011; 6(12):e29008. PMC: 3236224. DOI: 10.1371/journal.pone.0029008. View

11.

Agardh C, Cilio C, Lethagen A, Lynch K, Leslie R, Palmer M . Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005; 19(4):238-46. DOI: 10.1016/j.jdiacomp.2004.12.003. View

12.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

13.

Macfarlane G, El-Metwally A, de Silva V, Ernst E, Dowds G, Moots R . Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2011; 50(9):1672-83. DOI: 10.1093/rheumatology/ker119. View

14.

Huurman V, Decochez K, Mathieu C, Cohen I, Roep B . Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2006; 23(4):269-75. DOI: 10.1002/dmrr.691. View

15.

Wherrett D, Bundy B, Becker D, DiMeglio L, Gitelman S, Goland R . Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011; 378(9788):319-27. PMC: 3580128. DOI: 10.1016/S0140-6736(11)60895-7. View

16.

Voltarelli J, Couri C, Stracieri A, Oliveira M, Moraes D, Pieroni F . Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007; 297(14):1568-76. DOI: 10.1001/jama.297.14.1568. View

17.

Pozzilli P, Pitocco D, Visalli N, Cavallo M, Buzzetti R, Crino A . No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 2000; 43(8):1000-4. DOI: 10.1007/s001250051482. View

18.

Long S, Rieck M, Sanda S, Bollyky J, Samuels P, Goland R . Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012; 61(9):2340-8. PMC: 3425404. DOI: 10.2337/db12-0049. View

19.

Tyden G, Reinholt F, Sundkvist G, Bolinder J . Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med. 1996; 335(12):860-3. DOI: 10.1056/NEJM199609193351205. View

20.

Achenbach P, Barker J, Bonifacio E . Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep. 2008; 8(2):87-93. DOI: 10.1007/s11892-008-0017-y. View